ESPE Abstracts

Discussed in literature is primarily the impact of late-onset hypogonadism in men as a factor of development of endothelial dysfunction, insulin resistance and systemic inflammation, while the pathogenic role of hypoandrogenia in development of metabolic disorders in male individuals during puberty currently remains undetermined.Aim of research: To determine characteristics of lipid profile in adolescent boys with hypoandrogenia.Ma...

In recent years, the problem of androgen deficiency as a factor in the formation of dyslipidemia, endothelial dysfunction, insulin resistance and systemic inflammation has been studied mainly in adult men, because the main cause of mortality and disability in this cohort is cardiovascular disease. However, there are practically no data on the relationships of sex hormones with lipid metabolism during hypoandrogenism (HA) during puberty.Aim of research: w...

Background: Obesity in adults is closely associated with an increased prevalence of thyroid gland (TG) pathology, but thyropathy formation issues among children are not sufficiently studied.Objective and hypotheses: To determine the prevalence and structure of TG pathology in children with obesity by gender and degree of puberty.Method: In 121 patients 6–16 years old with obesity a thyropathy detection was conducted (diffuse n...

Delayed puberty (DP) in boys is considered the most common hypoandrogenia of puberty. It should be noted that DP adversely affects physical development, body formation and the health status of adolescents. The heterogeneity of the population of adolescents with DP has led to a differentiated approach and the allocation of the following three clinical options (CO) of DP: 1 - DP, accompanied by growth retardation; 2 - DP without significant deviations in physical development; 3 ...

Background: Thyroid dysfunction plays an important role in formation of dyslipidemia during obesity while thyroid pathology (TP) is one of the most common endocrinopathies associated with obesity. Among adults existence of gender differences has been proven in formation of a dyslipoproteiniaemias and thyropathies; the presence of such changes in obese children requires clarification.Objective and hypotheses: To explore the details of blood lipids in chil...

Background: Vascular Endothelial Growth Factor (VEGF) is largely produced by adipose tissue and is an important regulator of physiological and pathological angiogenesis in adults with obesity.Objective and hypotheses: To determine the nature of VEGF production and its connection to the formation of vascular complications in patients with childhood obesity.Method: In 87 children (42 boys and 45 girls) 9–17 years old with obesit...

Background: TransCon hGH is a long-acting prodrug of recombinant human growth hormone (hGH) that releases fully active unmodified hGH into the blood compartment. This presentation will detail the final safety and efficacy results of TransCon hGH in a Phase 2 study in children with GHD over a treatment period of six months.Objective and hypotheses: The objective of this Phase 2 study in GHD was to investigate 1) safety and tolerability, 2) pharmacokinetic...

Background: TransCon human GH (hGH) is a long-acting prodrug of recombinant hGH that releases fully active unmodified hGH. TransCon hGH was shown in phase 1 studies in healthy volunteers and a phase 2 study in adults with hGH deficiency to: i) be safe and well tolerated, ii) provide dose-dependent hGH levels, with same peak level and exposure compared to daily GH, iii) be suitable for a once-weekly dosing regimen, and iv) induce an IGF1 response within the normal range. This o...

GX-H9 is a long-acting form of recombinant human GH under clinical development for both adults and children with GH deficiency (GHD). This study was designed to compare 12-month effects of once-weekly and twice-monthly (every other week; EOW) administration of GX-H9 treatment to that of Genotropin®, in pediatric patients with GHD. A randomized, open-label, active-controlled, parallel study was conducted at 27 endocrinology centers in 10 countries (Europe and Ko...